VP16-213 (etoposide). A Critical Review of Its Activity

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1982 Jan 1

PMID 7044594

Citations 12

Authors

F Cavalli

Affiliations

Soon will be listed here.

Citing Articles

Schedule-dependent topoisomerase II-inhibiting drugs.

Joel S, Slevin M Cancer Chemother Pharmacol. 1994; 34 Suppl:S84-8.

PMID: 8070033 DOI: 10.1007/BF00684869.

Etoposide dosage and pharmacodynamics.

Joel S, Shah R, Slevin M Cancer Chemother Pharmacol. 1994; 34 Suppl:S69-75.

PMID: 8070031 DOI: 10.1007/BF00684867.

Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.

Lee J, Takahashi T, Hagiwara A, Yoneyama C, Itoh M, Sasabe T Cancer Chemother Pharmacol. 1995; 36(3):211-6.

PMID: 7781140 DOI: 10.1007/BF00685848.

A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease.

Ekert H, Fok T, Dalla-Pozza L, Waters K, Smith P, White L Br J Cancer. 1993; 67(1):159-62.

PMID: 7678978 PMC: 1968223. DOI: 10.1038/bjc.1993.28.

Treatment of acute myelogenous leukemia in children.

Schellong G, Creutzig U, Ritter J Med Oncol Tumor Pharmacother. 1985; 2(1):17-25.

PMID: 3863999 DOI: 10.1007/BF02934776.

References

Arnold A . Podophyllotoxin derivative VP 16-213. Cancer Chemother Pharmacol. 1979; 3(2):71-80. DOI: 10.1007/BF00254976. View

Nissen N, Larsen V, Pedersen H, Thomsen K . Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep. 1972; 56(6):769-77. View

. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. Br Med J. 1973; 3(5873):199-202. PMC: 1586276. View

Cavalli F, Klepp O, Renard J, Rohrt M, Alberto P . A phase II study of oral VP-16-213 in non-seminomatous testicular cancer. Eur J Cancer (1965). 1981; 17(2):245-9. DOI: 10.1016/0014-2964(81)90043-8. View

Nissen N, Dombernowsky P, Hansen H, Larsen V . PHASE I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep. 1976; 60(7):943-5. View

Cavalli F, SONNTAG R, Jungi F, Senn H, BRUNNER K . VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978; 62(3):473-5. View

Eagan R, Ingle J, Creagan E, Frytak S, Kvols L, Rubin J . VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep. 1978; 62(5):843-4. View

Issell B, Crooke S . Etoposide (VP-16-213). Cancer Treat Rev. 1979; 6(2):107-24. DOI: 10.1016/s0305-7372(79)80045-6. View

Lee Y, Catane R, Rozencweig M, BONO Jr V, Muggia F, Simon R . Analysis and interpretation of response rates for anticancer drugs. Cancer Treat Rep. 1979; 63(11-12):1713-20. View

10.

Rozencweig M, Von Hoff D, Henney J, Muggia F . VM 26 and VP 16-213: a comparative analysis. Cancer. 1977; 40(1):334-42. DOI: 10.1002/1097-0142(197707)40:1<334::aid-cncr2820400147>3.0.co;2-x. View

11.

Cavalli F . [Development of new substances in oncology. Many problems and some answers]. Dtsch Med Wochenschr. 1980; 105(26):909-10. DOI: 10.1055/s-2008-1070780. View

12.

Fitzharris B, Kaye S, Saverymuttu S, Newlands E, Barrett A, Peckham M . VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer (1965). 1980; 16(9):1193-7. DOI: 10.1016/0014-2964(80)90178-4. View

13.

Smith I, Gerken M, Clink H, McElwain T . VP 16-213 in acute myelogenous leukaemia. Postgrad Med J. 1976; 52(604):66-70. PMC: 2496302. DOI: 10.1136/pgmj.52.604.66. View

14.

Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen H . Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1981; 17(10):1079-82. DOI: 10.1016/0014-2964(81)90291-7. View

15.

FALKSON G, Van Dyk J, van Eden E, van der Merwe A, van den Bergh J, FALKSON H . A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213. Cancer. 1975; 35(4):1141-4. DOI: 10.1002/1097-0142(197504)35:4<1141::aid-cncr2820350418>3.0.co;2-3. View

16.

Hansen M, Hirsch F, Dombernowsky P, Hansen H . Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside). Cancer. 1977; 40(2):633-7. DOI: 10.1002/1097-0142(197708)40:2<633::aid-cncr2820400207>3.0.co;2-o. View

17.

FELIX W, Senn H . Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors. Cancer Chemother Rep. 1975; 59(4):737-42. View

18.

Lau M, Hansen H, Nissen N, Pedersen H . Phase I trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep. 1979; 63(3):485-7. View

19.

Staquet M, Rozencweig M, Von Hoff D, Muggia F . The delta and epsilon errors in the assessment of cancer clinical trials. Cancer Treat Rep. 1979; 63(11-12):1917-21. View

20.

Radice P, Bunn Jr P, Ihde D . Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep. 1979; 63(8):1231-9. View